BioSpace News Archive

Vyluma, Inc., a biopharmaceutical company developing multiple assets for the treatment of refractive errors, announced top-line results from its Phase III CHAMP clinical study.

Urovant Sciences today announced the recent publication of a Phase 1 study of the pharmacokinetic profile of GEMTESA (vibegron) 75mg in the peer-reviewed journal, Clinical Pharmacology in Drug Development. In the study, which involved healthy adults, GEMTESA was administered in a single 75-mg dose as an intact tablet vs. crushed and mixed with applesauce.

The American Diabetes Association® announced its recognition as a winner in the 2022 Sharecare Awards in the category of chronic diseases for The Big Step Up: Detection that encourages people to take the big step up for their health.

Following an extensive international search, Emory University announced that Ravi I. Thadhani, MD, MPH, has been appointed executive vice president for health affairs.

Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced it will report its financial results for the third quarter ended September 30, 2022, after the financial markets close on Monday, November 14, 2022.

Connect Biopharma Holdings Limited announced it will be presenting and/or hosting one-on-one meetings at the following upcoming investor and scientific conferences:

ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended September 30, 2022.

Rila Therapeutics, a biotherapeutics company focused on addressing the critical unmet medical needs to treat renal fibrosis, announced its emergence out of stealth mode.

Zynex, Inc. an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, reported financial results for the third quarter ended September 30, 2022.

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report third quarter fiscal year 2022 financial results on Wednesday, November 9, 2022, after the close of the market.